GHDDI aims to become a major biomedical research center of excellence with a broad focus on
translational research - from the bench to the bedside.


Scientists at GHDDI work across a wide range of diseases that disproportionately affect populations in the developing world, including but not limited to tuberculosis, malaria, helminth infections, diarrheal disease, etc.


Projects will come from GHDDI internal efforts, BMGF, solicitations from leading academic investigators and organizations (such as Calibr). All proposals will be evaluated based on innovation and differentiation, relevance to unmet medical needs, technical feasibility, and available expertise. Projects within GHDDI will progress through a series of stages with modular activity - and compound-based milestones required to deliver pre-clinical and clinical candidates.



The Repurposing, Focused Rescue, and Accelerated Medchem (ReFRAME) Initiative serves as a scheme of high-value screening for expedited drug discovery. As shown in previous studies, initiating drug discovery campaigns from known drugs or compounds that have adequate clinical safety/PK (either direct repurposing or as mature leads) significantly decreases the cost and time associated with finding new therapies. A consolidated, comprehensive library of such compounds will greatly enable and accelerate new drug discovery efforts, and allow high-value assays to be deployed, making this especially useful in challenging therapeutic areas that have a paucity of leads.

The compounds in the ReFRAME library were identified using several databases and specially developed informatics. Identified compounds were acquired through commercial vendors and customized synthesis, and QCed by in-house analysis. The ReFRAME library has now collected ~12,000 compounds demonstrated safe in human. We will establish a framework for screening and sharing the library, making it available under Global Access terms to investigators working on unmet global health needs. The development of the library was led by Calibr and funded by BMGF.